Sunesis Pharmaceuticals, Inc. · South San Francisco, CA United States (NASDAQ: SNSS)
| 395 Oyster Point Blvd., Ste. 400 | Phone: 650-266-3500 |
| South San Francisco, CA | Fax: 650-266-3505 |
| 94080 | |
| United States | 
Map This Company |
Sunesis Pharmaceuticals, Inc. Rankings
| Russell 2000 (June 2011) |
More Companies in These Related Industries: Pharmaceutical Preparation MfgCompany Description
Sunesis builds drugs in miniature first before it builds them in full scale. The biotech firm's method involves building small drug fragments and then examining their protein-binding ability and potential for development. Once a fragment shows potential, Sunesis then builds a larger therapeutic compound based upon its model. Its drug candidates target various forms of cancer. Its lead candidate Vosaroxin (SNS-595) is in clinical trials to evaluate its effect on ovarian cancer and acute myeloid leukemia. Other candidates are being studied for treatment of solid tumors and other forms of cancer, both independently and through partnerships.
Sunesis Pharmaceuticals, Inc. Reports
No subscription, no problem.
Download presentation-ready reports. From company profiles to the competitive landscape, Hoover's offers immediate access to individual reports.
Financials
| Company Type | Public - NASDAQ: SNSS Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2011 Employees | 31 |
Executives
27 executives listed for Sunesis Pharmaceuticals, Inc.'s South San Francisco, CA location.
| Chairman | James Young | |
|---|---|---|
| President, CEO, and Director | Daniel Swisher | |
| SVP Corporate Development and Finance, CFO, and Corporate Secretary | Eric Bjerkholt |